INSPIRING INNOVATION

Fiscal Year 2017 Annual Report: July 1, 2016 – June 30, 2017
Dear Friends and Supporters,

It is now estimated that there are more than one million people in the United States currently living with some form of lymphoma and chronic lymphocytic leukemia (CLL). For some, this seemingly growing number may seem daunting, but we at the Lymphoma Research Foundation (LRF) are more prepared than ever to meet the evolving needs of today’s lymphoma community.

We are encouraged that this number reflects an increase in those living with their disease, as mortality rates from blood cancers continue to fall and patient outcomes improve. With nearly a half-dozen new drugs approved for the treatment of lymphoma and CLL in the last fiscal year alone, we take pride in the knowledge that LRF’s educational resources have helped patients and their loved ones become their own healthcare advocates, armed with the knowledge they need about these new developments so that they can make the most informed decisions based on their individual needs. We are inspired by the resilience of this million-person strong community, and we pledge our continued support to the research that is transforming lymphoma survivors into lymphoma thrivers.

As the nation’s largest non-profit organization devoted to funding innovative research and serving the lymphoma community through comprehensive series of education programs, outreach initiatives and patient services, the Lymphoma Research Foundation remains unwavering in our mission to eradicate lymphoma and serve those impacted by this blood cancer. As novel treatments continue to advance, LRF will fund and support the young investigators at the forefront of these breakthroughs, as evidenced by the more than 200 past and present LRF grantees that presented at the 58th American Society of Hematology Annual Meeting. In the following pages, we will celebrate the researchers that represent some of the most impactful scientific research in hematology today, all of whom are committed to partnering with LRF as we work together to find a cure.

As we remain focused on our mission, we must support individual researchers by not only continuing to fund their groundbreaking science, but also ensuring that these results can be utilized by the patients who need it most. Over the next year, we will continue to develop new, innovative fundraising partnerships and expand program collaborations to ensure that we are able to meet the challenges of today’s lymphoma landscape. It is our hope that by continuing to create new fundraising opportunities, we can not only empower the researchers themselves, but also the patients who benefit from this research as well. We will continue to provide exceptional education to those who need it most and ensure that patients and loved ones across the country are able to access critical disease information.

With your continued support, we hope to cure lymphoma within our lifetime by funding our nation’s best and brightest blood cancer researchers. We thank you for your assistance throughout our 2017 Fiscal Year in helping the Lymphoma Research Foundation to inspire innovation in everything we do.

Michael Werner, Chair, Board of Directors,
Lymphoma Research Foundation
Meghan Gutierrez, Chief Executive Officer,
Lymphoma Research Foundation

In the following pages, we will celebrate the researchers that represent some of the most impactful scientific research in hematology today, all of whom are committed to partnering with LRF as we work together to find a cure.

Table of Contents
01 Letter from the CEO and Chair
02 Inspiring Impact
04 Scientific Advisory Board Spotlight
06 Early-Career Investigator Spotlight
08 Career Development Award Spotlight
10 Postdoctoral Fellowship Spotlight
12 Fiscal Year 2017 LRF Highlights
14 Financials
16 Scientific Advisory Board
17 Board of Directors
18 Individual, Estate and Foundation Donors
22 Corporate Sponsors
23 Top Team LRF Fundraisers
24 Walk and Ride Teams
Every five minutes, someone in the United States is diagnosed with some form of lymphoma and CLL.

The Lymphoma Research Foundation has funded more than $60 million in lymphoma research, which has resulted in more than 370 grants to-date.

LRF funds more than 40,000 research hours each year for early-career scientists, enabling young investigators to maintain a research focus on lymphoma.

More than 1,000,000 patients and caregivers access LRF’s digital resources annually, empowering patients and their loved ones to become their own advocates in the healthcare process.
The Lymphoma Research Foundation’s Scientific Advisory Board (SAB) is comprised of 45 world-renowned lymphoma experts who guide all investment of LRF’s research portfolio. As representatives from some of North America’s preeminent cancer research centers, LRF’s SAB members not only seek out the most innovative and promising lymphoma research projects for support, but also generously donate their time and talents to LRF’s in-person educational programming, disease-specific publications, and young investigator mentoring initiatives. Together, the Scientific Advisory Board is able to set an aggressive research agenda through collaborative investigation opportunities to ensure that LRF’s research can have the greatest impact on today’s lymphoma community.

Professional Highlights
• Authored studies of 21 different drugs in lymphoproliferative disorders since 1985
• Helped to build the Mayo Clinic’s lymphoma program alongside LRF SAB members Dr. Thomas Witzig and Dr. Stephen Ansell
• Established the infrastructure for databases and tissue banks including the Mayo Clinic Lymphoma database

Research Focus
With more than 90 subtypes, Dr. Habermann focuses on synthesizing big data in a meaningful way to help advance the understanding of lymphoproliferative disorders and achieve more personalized treatments with the individual patient in mind.

Mission Moment
“As the Chair of the Lymphoma Research Foundation’s Scientific Advisory Board, I look forward to the opportunity to help guide the collective knowledge of this 45-world leading minds in the field toward our common pursuit of a cure, while ensuring that today’s young investigators have the resources and the mentorship needed to maintain their commitment to the study of blood cancer is a critical part of my work with LRF.”

Scientific Advisory Board Spotlight

Thomas M. Habermann, MD
• Mayo Clinic, Rochester
• Chair, Lymphoma Research Foundation Scientific Advisory Board

“Imagine Innovation”

Final Year 2017 Annual Report
The Lymphoma Research Foundation has made significant investments in blood cancer research—awarding more than 300 research grants totaling more than $60 million to date. Since its inception, LRF has focused its funding on early-career scientists with particular promise in the field. In 2014, LRF developed the first-of-its-kind Lymphoma Clinical Research Mentoring Program (LCRMP), offering mentorship and education to hematologic/oncology fellows and junior faculty dedicated to clinical research in the field of non-Hodgkin lymphoma, Hodgkin lymphoma, and CLL. Program participants, called LRF Scholars, attend and participate in a week-long intensive introductory workshop and follow-up programming intended to enhance the ability of the LRF Scholars to successfully design and administer clinical research studies and successfully apply for future grant funding. This unique focus on funding today’s early-career investigators ensures that these brilliant young minds are able to remain dedicated to blood cancer research throughout their careers.

**Early-Career Investigator Spotlight**

**Connie Batlevi, MD, PhD**  
- Memorial Sloan Kettering Cancer Center  
- LRF Scholar

**Professional Highlights**
- Matriculated from Memorial Sloan Kettering Cancer Center Medical Oncology fellowship after completing her residency at Mount Sinai Medical Center
- Participated in 2016 Lymphoma Clinical Research Mentoring Program (LCRMP), researching Bruton’s tyrosine kinase (BTK) and phosphoinositide 3 kinase (PI3K) inhibitors
- Presented her LCRMP project findings at the 2017 International Conference on Malignant Lymphomas, one of the few early-career scientists to be invited to give an oral presentation at this prestigious international event due to the far-reaching implications of her LRF funded research

**Research Focus**
Understanding that Bruton’s tyrosine kinase (BTK) and phosphoinositide 3 kinase (PI3K) inhibitors have yielded extraordinary results in the clinical setting as standalone treatments, Dr. Batlevi seeks to improve the depth and duration of response using these two therapies attacking separate pathways in a tandem approach.

**Mission Moment**
"The next 20 years will undoubtedly bring the excitement of applying the knowledge gained from understanding cancer genomics, biologic synergism, and immune therapy to lymphoma management. This dynamic environment is ideal for young investigators like myself to grow and learn about rationally-designed, patient-oriented clinical research, and LRF’s support has been vital in my ability to take part in this exciting research."

"Inspiring Innovation"
In an effort to ensure that mid-career scientists are able to maintain their commitment to blood cancer research as they transition between young investigators and subject matter experts, the Lymphoma Research Foundation developed its Career Development Award in 2002. Applicants must be within five years of the completion of their postdoctoral training and must spend at least 35 percent of their time in independent clinical research. The Larry and Denise Mason Career Development Award (CDA) was named in honor of acclaimed New York City artist Larry Mason and his wife, Denise, who passed away from lymphoma in 2003, and is granted to the award recipient whose research has the potential to have the widest ranging impact across all lymphomas. The Career Development Award program is designed to provide a platform for midcareer scientists to continue in their development as tomorrow’s leaders in the world of lymphoma research.

Career Development Award Spotlight

Alex F. Herrera, MD
- Beckman Research Institute of the City of Hope
- CDA Grantee and Former LRF Scholar

Professional Highlights
- Named Assistant Professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope
- Won American Society of Blood and Marrow Transplantation/Biology of Blood and Marrow Transplantation George Santos Award for Best Clinical Science Article by a New Investigator
- Participated in the 2016 LRF Lymphoma Clinical Research Mentoring Program

Research Focus
Through his grant studying pembrolizumab plus vorinostat for the treatment of relapsed or refractory lymphomas, Dr. Herrera will evaluate the safety of unique novel drug therapy combinations for treatment of Hodgkin and non-Hodgkin lymphomas that have recurred or not responded to initial therapy.

Mission Moment
“Immunotherapy represents an exciting area of interest in the treatment of all lymphomas, but it can provide particular hope to patients with chemo-resistant disease who have traditionally been faced with limited treatment options in the past. We hope that this study can show that this immunotherapy combination is safe and effective, and that it ultimately may help improve outcomes for patients throughout the country. LRF’s research funding will enable us to gain a deeper understanding of the underlying biological factors that lead to treatment response or resistance.”
A part of the Lymphoma Research Foundation’s grant portfolio since 1992, LRF’s Postdoctoral Fellowships support young professionals in the first five years of their career. Grantees must spend at least 80 percent of their time in research; their two-year award provides salary support, professional development, and research expenses. Postdoctoral Fellowship Grants are open to clinical research projects as well as translational research geared toward moving new discoveries to the clinical setting. With more than 230 Fellowships awarded since its inception, the Postdoctoral Fellowship program provides early-career scientists with the resources they need to turn their innovative ideas into evidence-based practice.

Postdoctoral Fellowship Spotlight

Jouliana Sadek, PhD
• Weill Cornell Medicine
• LRF Postdoctoral Fellow

Professional Highlights
• Serves as a Postdoctoral Associate in the lab of current SAB member Ethel Cesarman, MD, PhD at Weill Cornell Medicine
• Discovered a novel nucleoside analog called 6-ethylthioinosine, a chemotherapeutic agent that can selectively target cancers of the plasma cells.
• Helped to establish the enzyme adenine kinase (ADK) as a predictor to therapy response

Research Focus
Given that Dr. Sadek’s compound has a promising potential for the treatment of aggressive tumors and that ADK expression can be used as a biomarker for response, she hopes to further understand the underlying biology behind these cells and develop effective drug combinations that can have the greatest impact on patient outcomes.

Mission Moment
“When I volunteered at a pediatric cancer center in high school, I realized then that I had an insatiable desire to be active in the fight against cancer. LRF’s support has enabled me to leverage my scientific knowledge and training to play an active role in serving lymphoma patients and to develop novel therapeutic interventions that can give hope to patients who failed other treatment options. Our research seeks to identify effective drug combinations and deliver targeted treatment to patients suffering from plasma cell malignancies, and LRF’s fellowship has enabled me to see this research through.”

Professional Highlights
• Serves as a Postdoctoral Associate in the lab of current SAB member Ethel Cesarman, MD, PhD at Weill Cornell Medicine
• Discovered a novel nucleoside analog called 6-ethylthioinosine, a chemotherapeutic agent that can selectively target cancers of the plasma cells.
• Helped to establish the enzyme adenine kinase (ADK) as a predictor to therapy response

Research Focus
Given that Dr. Sadek’s compound has a promising potential for the treatment of aggressive tumors and that ADK expression can be used as a biomarker for response, she hopes to further understand the underlying biology behind these cells and develop effective drug combinations that can have the greatest impact on patient outcomes.

Mission Moment
“When I volunteered at a pediatric cancer center in high school, I realized then that I had an insatiable desire to be active in the fight against cancer. LRF’s support has enabled me to leverage my scientific knowledge and training to play an active role in serving lymphoma patients and to develop novel therapeutic interventions that can give hope to patients who failed other treatment options. Our research seeks to identify effective drug combinations and deliver targeted treatment to patients suffering from plasma cell malignancies, and LRF’s fellowship has enabled me to see this research through.”

Mission Moment
“When I volunteered at a pediatric cancer center in high school, I realized then that I had an insatiable desire to be active in the fight against cancer. LRF’s support has enabled me to leverage my scientific knowledge and training to play an active role in serving lymphoma patients and to develop novel therapeutic interventions that can give hope to patients who failed other treatment options. Our research seeks to identify effective drug combinations and deliver targeted treatment to patients suffering from plasma cell malignancies, and LRF’s fellowship has enabled me to see this research through.”
Fiscal Year 2017
LRF Highlights

July 1, 2016 – June 30, 2017

**RESEARCH**
- More than $7 million in active research grants
- More than 17 early-career investigators received grant funding
- More than 40% increase in early-career program applications

**EDUCATION**
- More than 1,000,000 patients, caregivers, and their loved ones accessed LRF’s digital educational resources
- More than 4,800 downloads of LRF’s Focus on Lymphoma mobile health app
- More than 2,500 individuals served by LRF in-person education events

**SUPPORT**
- More than 10,000 inquiries to the Lymphoma Helpline
- More than 10,000 downloads of Patient Guidelines and Fact Sheets
- More than 226 new members in the Lymphoma Support Network

**DEVELOPMENT**
- More than $300,000 raised through individual TeamLRF events
- More than 50 unique fundraising events held throughout the country
- More than $1.3 M raised through Active Lifestyles events
# Financials

## For the fiscal year ended June 30, 2017

### LYMPHOMA RESEARCH FOUNDATION BALANCE SHEETS

<table>
<thead>
<tr>
<th></th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>$1,280</td>
<td>$1,207</td>
</tr>
<tr>
<td>Investments</td>
<td>$9,861</td>
<td>$8,711</td>
</tr>
<tr>
<td>Contributions and grants receivable</td>
<td>$277</td>
<td>$297</td>
</tr>
<tr>
<td>Prepaid expenses and other assets</td>
<td>$1,057</td>
<td>$373</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td>$12,675</td>
<td>$10,580</td>
</tr>
</tbody>
</table>

| **Liabilities & Net Assets** |              |              |
| Research grants payable   | $2,985       | $2,506       |
| Refundable advances       | $135         | $95          |
| Accounts payable and accrued expenses | $177       | $176        |
| Program services           | $212         | $187         |
| **Total liabilities**      | $3,597       | $2,962       |

| **Unrestricted net assets** |              |              |
| Special events and other revenue | $1,057    | $373        |
| Program services           | $212         | $187         |
| Other activities and expenses of operations | $177       | $176        |
| Administration expenses    | $65          | $50          |
| **Total liabilities and net assets** | $12,675  | $10,580      |

### LYMPHOMA RESEARCH FOUNDATION CONDENSED STATEMENT OF ACTIVITIES

<table>
<thead>
<tr>
<th></th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Unrestricted Contributions &amp; Revenues</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Special events revenues &amp; contributions</td>
<td>$4,934</td>
<td>$4,680</td>
</tr>
<tr>
<td>Investment &amp; other income</td>
<td>$76</td>
<td>$97</td>
</tr>
<tr>
<td>Contributions &amp; revenues</td>
<td>$7,010</td>
<td>$6,777</td>
</tr>
<tr>
<td><strong>Total contributions &amp; revenues</strong></td>
<td>$10,782</td>
<td>$10,473</td>
</tr>
</tbody>
</table>

| **Program services** |              |              |
| Research services    | $2,985       | $2,506       |
| Education programs and patient services | $135       | $95          |
| Communications and advocacy | $122       | $187         |
| **Total expenses**   | $7,764       | $7,010       |

| **Increase in unrestricted net assets** |              |              |
| Special events and other revenue | $277        | $276         |
| Other activities and expenses of operations | $421       | $156         |
| **Increase in net assets** | $1,148      | $531         |

The Condensed Balance Sheets and Statements of Activities of the Lymphoma Research Foundation as of June 30, 2017 and 2016 have been derived from LRF’s audited financial statements. The Lymphoma Research Foundation’s complete set of audited financial statements and related information can be found on the Lymphoma Research Foundation’s website, lymphoma.org/annual report. The Financial Statements have been audited by KPMG LLP.
Individual, Estate, and Foundation Donors

2016–2017

July 1, 2016 – June 30, 2017

Joan K. Eigen
Mr. and Mrs. Gary Davis
Dorothy Carpenter
The Bruning Foundation
Mr. John Ballantine
Dr. and Mrs. Carlton Alexis
Mr. Oded Aboodi

$5,000 to $9,999

Dr. Adelaide W. Zabriskie
Targoff Family Foundation
Mr. and Mrs. Ronald Shear
Mr. Taylor O. Barber
Richie Carter

$25,000 to $49,999

The Goldstone Fund
Arlene and Robert Fischer/
The Condon Family Foundation

Mr. and Mrs. Gary D. Hirsch
Family of John Grando
Nancy Goldman
Gantcher Family Foundation

$10,000 to $24,999

Mr. Jeffrey Walker and Ms. Sharon Wurtzel
The John and Louise Steegstra Memorial Fund
Mr. Steven E. Rosen
David and Miriam Phalen and
Leigh and Cory Olson

Mr. and Mrs. John Dowd
Anonymous (4)

$5,000 to $9,999

Dr. Adelaide W. Zabriskie
Targoff Family Foundation
Mr. John Ballantine
Dr. and Mrs. Carlton Alexis
Mr. Oded Aboodi


Individual, Estate, and Foundation Donors

2016–2017

July 1, 2016 – June 30, 2017

Joan K. Eigen
Mr. and Mrs. Gary Davis
Dorothy Carpenter
The Bruning Foundation
Mr. John Ballantine
Dr. and Mrs. Carlton Alexis
Mr. Oded Aboodi

$5,000 to $9,999

Dr. Adelaide W. Zabriskie
Targoff Family Foundation
Mr. and Mrs. Ronald Shear
Mr. Taylor O. Barber
Richie Carter

$25,000 to $49,999

The Goldstone Fund
Arlene and Robert Fischer/
The Condon Family Foundation

Mr. and Mrs. Gary D. Hirsch
Family of John Grando
Nancy Goldman
Gantcher Family Foundation

$10,000 to $24,999

Mr. Jeffrey Walker and Ms. Sharon Wurtzel
The John and Louise Steegstra Memorial Fund
Mr. Steven E. Rosen
David and Miriam Phalen and
Leigh and Cory Olson

Mr. and Mrs. John Dowd
Anonymous (4)

$5,000 to $9,999

Dr. Adelaide W. Zabriskie
Targoff Family Foundation
Mr. John Ballantine
Dr. and Mrs. Carlton Alexis
Mr. Oded Aboodi


Individual, Estate, and Foundation Donors

2016–2017

July 1, 2016 – June 30, 2017

Joan K. Eigen
Mr. and Mrs. Gary Davis
Dorothy Carpenter
The Bruning Foundation
Mr. John Ballantine
Dr. and Mrs. Carlton Alexis
Mr. Oded Aboodi

$5,000 to $9,999

Dr. Adelaide W. Zabriskie
Targoff Family Foundation
Mr. and Mrs. Ronald Shear
Mr. Taylor O. Barber
Richie Carter

$25,000 to $49,999

The Goldstone Fund
Arlene and Robert Fischer/
The Condon Family Foundation

Mr. and Mrs. Gary D. Hirsch
Family of John Grando
Nancy Goldman
Gantcher Family Foundation

$10,000 to $24,999

Mr. Jeffrey Walker and Ms. Sharon Wurtzel
The John and Louise Steegstra Memorial Fund
Mr. Steven E. Rosen
David and Miriam Phalen and
Leigh and Cory Olson

Mr. and Mrs. John Dowd
Anonymous (4)

$5,000 to $9,999

Dr. Adelaide W. Zabriskie
Targoff Family Foundation
Mr. John Ballantine
Dr. and Mrs. Carlton Alexis
Mr. Oded Aboodi


Individual, Estate, and Foundation Donors

2016–2017

July 1, 2016 – June 30, 2017

Joan K. Eigen
Mr. and Mrs. Gary Davis
Dorothy Carpenter
The Bruning Foundation
Mr. John Ballantine
Dr. and Mrs. Carlton Alexis
Mr. Oded Aboodi

$5,000 to $9,999

Dr. Adelaide W. Zabriskie
Targoff Family Foundation
Mr. and Mrs. Ronald Shear
Mr. Taylor O. Barber
Richie Carter

$25,000 to $49,999

The Goldstone Fund
Arlene and Robert Fischer/
The Condon Family Foundation

Mr. and Mrs. Gary D. Hirsch
Family of John Grando
Nancy Goldman
Gantcher Family Foundation

$10,000 to $24,999

Mr. Jeffrey Walker and Ms. Sharon Wurtzel
The John and Louise Steegstra Memorial Fund
Mr. Steven E. Rosen
David and Miriam Phalen and
Leigh and Cory Olson

Mr. and Mrs. John Dowd
Anonymous (4)

$5,000 to $9,999

Dr. Adelaide W. Zabriskie
Targoff Family Foundation
Mr. John Ballantine
Dr. and Mrs. Carlton Alexis
Mr. Oded Aboodi


Individual, Estate, and Foundation Donors

2016–2017

July 1, 2016 – June 30, 2017

Joan K. Eigen
Mr. and Mrs. Gary Davis
Dorothy Carpenter
The Bruning Foundation
Mr. John Ballantine
Dr. and Mrs. Carlton Alexis
Mr. Oded Aboodi

$5,000 to $9,999

Dr. Adelaide W. Zabriskie
Targoff Family Foundation
Mr. and Mrs. Ronald Shear
Mr. Taylor O. Barber
Richie Carter

$25,000 to $49,999

The Goldstone Fund
Arlene and Robert Fischer/
The Condon Family Foundation

Mr. and Mrs. Gary D. Hirsch
Family of John Grando
Nancy Goldman
Gantcher Family Foundation

$10,000 to $24,999

Mr. Jeffrey Walker and Ms. Sharon Wurtzel
The John and Louise Steegstra Memorial Fund
Mr. Steven E. Rosen
David and Miriam Phalen and
Leigh and Cory Olson

Mr. and Mrs. John Dowd
Anonymous (4)

$5,000 to $9,999

Dr. Adelaide W. Zabriskie
Targoff Family Foundation
Mr. John Ballantine
Dr. and Mrs. Carlton Alexis
Mr. Oded Aboodi


Individual, Estate, and Foundation Donors

2016–2017

July 1, 2016 – June 30, 2017

Joan K. Eigen
Mr. and Mrs. Gary Davis
Dorothy Carpenter
The Bruning Foundation
Mr. John Ballantine
Dr. and Mrs. Carlton Alexis
Mr. Oded Aboodi

$5,000 to $9,999

Dr. Adelaide W. Zabriskie
Targoff Family Foundation
Mr. and Mrs. Ronald Shear
Mr. Taylor O. Barber
Richie Carter

$25,000 to $49,999

The Goldstone Fund
Arlene and Robert Fischer/
The Condon Family Foundation

Mr. and Mrs. Gary D. Hirsch
Family of John Grando
Nancy Goldman
Gantcher Family Foundation

$10,000 to $24,999

Mr. Jeffrey Walker and Ms. Sharon Wurtzel
The John and Louise Steegstra Memorial Fund
Mr. Steven E. Rosen
David and Miriam Phalen and
Leigh and Cory Olson

Mr. and Mrs. John Dowd
Anonymous (4)

$5,000 to $9,999

Dr. Adelaide W. Zabriskie
Targoff Family Foundation
Mr. John Ballantine
Dr. and Mrs. Carlton Alexis
Mr. Oded Aboodi


Individual, Estate, and Foundation Donors

2016–2017

July 1, 2016 – June 30, 2017

Joan K. Eigen
Mr. and Mrs. Gary Davis
Dorothy Carpenter
The Bruning Foundation
Mr. John Ballantine
Dr. and Mrs. Carlton Alexis
Mr. Oded Aboodi

$5,000 to $9,999

Dr. Adelaide W. Zabriskie
Targoff Family Foundation
Mr. and Mrs. Ronald Shear
Mr. Taylor O. Barber
Richie Carter

$25,000 to $49,999

The Goldstone Fund
Arlene and Robert Fischer/
The Condon Family Foundation

Mr. and Mrs. Gary D. Hirsch
Family of John Grando
Nancy Goldman
Gantcher Family Foundation

$10,000 to $24,999

Mr. Jeffrey Walker and Ms. Sharon Wurtzel
The John and Louise Steegstra Memorial Fund
Mr. Steven E. Rosen
David and Miriam Phalen and
Leigh and Cory Olson

Mr. and Mrs. John Dowd
Anonymous (4)
Individual, Estate and Foundation Donors (Continued)

July 1, 2016 – June 30, 2017

Inspiring Innovation
Walk and Ride Teams
2016-2017
July 1, 2016 – June 30, 2017

$100,000+
Cheson Riders

$25,000 to $99,999
Lucky Moz Yip
Laura’s Love LymphoMates
S2 (Supporters and Survivors)
Team Assuncao
Team Sarnoff
Team Taverna
Team W

$10,000 to 24,999
Las Ventanas
Lymphomaniacs
Nancy & Tony’s Cancer Fighting Ninjas
Team PETER + MARK
Team Ragan
The Frank Futzers
Union Pacific
Weirdo’s Eagles
You’re the Cure!

$5,000 to $9,999
BROOKLYMPHOMA JC
Buffett Cancer Center Lymphomaniacs
Carly’s Cure
Holland & Knight
HSPH Lymphoma With Team Kathy
Mimi’s Marchers
Missy’s Misfits
Papa’s Legacy
Remembering Dan’s Journey
Remission Riders
STEPPIN OUT FOR SHAR
STICKWALKERS
Team DeSimone
Team Hooper
Team NXP
Team Riordan
Team SGEN
TEAM VAUGHAN
Team Vera

Team Yang & Friends
The Irish Whisper
The Knockouts
Tumor Raiders
We Can Do It
You can help the Lymphoma Research Foundation remain at the forefront of lymphoma research.

lymphoma.org/donate